BH3 Mimetics in AML Therapy: Death and Beyond?

Animals Antineoplastic Agents / pharmacology Biomimetic Materials / pharmacology Clinical Trials, Phase I as Topic Humans Leukemia, Myeloid, Acute / drug therapy Protein Domains Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
BCL2 proteins acute myeloid leukemia natural and synthetic BH3 mimetics targeted combinatorial strategies

Journal

Trends in pharmacological sciences
ISSN: 1873-3735
Titre abrégé: Trends Pharmacol Sci
Pays: England
ID NLM: 7906158

Informations de publication

Date de publication:
11 2020
Historique:
received: 09 04 2020
revised: 01 09 2020
accepted: 10 09 2020
pubmed: 10 10 2020
medline: 8 6 2021
entrez: 9 10 2020
Statut: ppublish

Résumé

B cell lymphoma 2 (BCL2) homology domain 3 (BH3) mimetics are targeted therapeutic agents that allow response prediction and patient stratification. BH3 mimetics are prototypical activators of the mitochondrial death program in cancer. They emerged as important modulators of cellular mechanisms contributing to poor therapeutic responses, including cancer cell stemness, cancer-specific metabolic routes, paracrine signaling to the tumor microenvironment, and immune modulation. We present an overview of the antagonism between BH3 mimetics and antiapoptotic BCL2 proteins. We focus on acute myeloid leukemia (AML), a cancer with reduced therapeutic options that have recently been improved by BH3 mimetics.

Identifiants

DOI: 10.1016/j.tips.2020.09.004 PMID: 33032835
pubmed: 33032835
pii: S0165-6147(20)30210-8
doi: 10.1016/j.tips.2020.09.004
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Proto-Oncogene Proteins c-bcl-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

793-814

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Claudia Cerella (C)

Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, L-2540 Luxembourg, Luxembourg.

Mario Dicato (M)

Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, L-2540 Luxembourg, Luxembourg.

Marc Diederich (M)

Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul 151-742, South Korea. Electronic address: marcdiederich@snu.ac.kr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › BH3 Mimetics in AML Therapy: Death and Beyond?
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › BH3 Mimetics in AML Therapy: Death and Beyond?
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomimétiques › BH3 Mimetics in AML Therapy: Death and Beyond?
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques de phase I comme sujet › BH3 Mimetics in AML Therapy: Death and Beyond?
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › BH3 Mimetics in AML Therapy: Death and Beyond?
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › BH3 Mimetics in AML Therapy: Death and Beyond?
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Conformation moléculaire › Conformation des protéines › Structure tertiaire des protéines › Domaines protéiques › BH3 Mimetics in AML Therapy: Death and Beyond?
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes c-bcl-2 › BH3 Mimetics in AML Therapy: Death and Beyond?